In mouse models of breast cancer and melanoma, increased TGF-β signaling suppresses tumor progression by increasing indoleamine 2,3-dioxygenase (IDO) in pDCs and increasing secretion of the myeloid cell attractor CCL22 (126). Here, TGFB1 is linked to melanoma.